Researchers at the University of Texas MD Anderson Cancer Center have developed a novel antibody-toxin conjugate (ATC) ...

Live webcasts of these events will be available on the Investors & Media section of Mersana’s website at www.mersana.com. Archived replays will be available for approximately 90 days following the ...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific ...

WuXi XDC Cayman Inc. ('WuXi XDC', or the 'Company', stock code: 2268.HK), a leading global CRDMO (Contract Research, ...

Researchers at The University of Texas MD Anderson Cancer Center have developed a novel antibody-toxin conjugate (ATC) designed to stimulate ...

Pfizer has partnered with Summit Therapeutics to evaluate ivonescimab, a PD-1/VEGF bispecific antibody, in combination with ...

Akeso, Inc. (9926.HK) ('Akeso' or the 'Company') today announced that its partner on ivonescimab, Summit Therapeutics Inc. (NASDAQ: SMMT) has entered into a clinical trial collaboration with Pfizer ...

There's an arms race in medicine—scientists design drugs to treat lethal bacterial infections, but bacteria can evolve ...

Summit Therapeutics established a clinical trial collaboration with Pfizer to develop ivonescimab for NSCLC and solid tumors.